West Pharmaceutical is in a sustained, powerful uptrend: the stock is up 43.73% over the past year and 38.94% year-to-date, massively outperforming the S&P 500's 15.53% and 11.93% respective gains, with relative strength of +28.20 percentage points over one year. At $384.02, the shares sit at roughly 99.4% of the 52-week range (low $223.83, high $386.22), just below the upper boundary, which signals strong momentum but also meaningful overextension risk and little margin of safety for new entries at current levels. The 180-day price series confirms a persistent stair-step advance from the ~$278 April level to the mid-$380s, with higher lows intact throughout. Recent momentum is positive but more measured: the stock is up 6.08% over one month and 7.20% over three months, with one-month relative strength of +4.86 points versus SPY's 1.22% gain, indicating the uptrend is intact rather than decelerating. The six-month change of 40.29% versus the one-month 6.08% shows momentum has cooled from its spring/summer pace, consistent with consolidation near highs rather than a reversal; the July 24 gap from $355.48 to $328.20 (a roughly 7.7% single-day drop) marked the sharpest recent distribution event, but the stock fully recovered and made new highs by October. Key resistance sits at the 52-week high of $386.22, roughly 0.6% above the current $384.02 close; a decisive breakout would confirm trend continuation and likely invite momentum buying, while failure and rejection could set up a double-top. Support is anchored at the 52-week low of $223.83, with intermediate support around the $355-365 breakout zone and the July gap area near $328; a break below $355 would signal trend damage. With a beta of 1.125, the stock is about 12.5% more volatile than the market, and a max drawdown of -24.83% over the period underscores that position sizing should account for above-market swing risk despite the stock's defensive-sector label.

Revenue is growing at a healthy, re-accelerating pace: Q2 2026 revenue of $872.3 million rose 13.85% year over year versus $766.2 million in Q2 2025, and the sequential trajectory ($844.9M in Q1 2026, $805.0M in Q4 2025, $804.3M in Q3 2025) shows consistent upward progression. The Q2 print represents the strongest YoY growth in the visible series, with Q1 2026 revenue of $844.9 million up roughly 21% from $698.2 million in Q1 2025, confirming acceleration tied to GLP-1 and biologics demand. Segment disclosure shows Proprietary Products at $722.6 million and West Vantage at $149.7 million, with the high-value proprietary franchise (about 80% of revenue) driving the mix and the growth story. The trajectory supports the raised-guidance narrative and implies the investment case rests on volume-led growth in injectable components rather than price. Profitability is robust and improving: Q2 2026 net income was $154.0 million on a 17.65% net margin, with gross margin of 37.74% and operating margin of 20.53%, and gross margin expanded from 35.08% in Q1 2026 and 35.66% in Q2 2025. The Q2 gross margin of 37.74% is the highest in the recent series, and net income rose from $131.8 million in Q2 2025 to $154.0 million, a roughly 17% increase, outpacing revenue growth and signaling operating leverage. The TTM net margin of 16.06% and operating margin of 20.09% are consistent with a high-quality medical-supplies franchise, though below the 2022-2023 peak operating margins of 23-29%, leaving room for further recovery. The balance sheet is fortress-like: debt-to-equity is just 0.131, the current ratio is 3.02, and cash stood at $435.8 million at Q2 2026 after $297.6 million of buybacks in the quarter. Free cash flow TTM is $436.9 million, though quarterly FCF has been lumpy ($80.8M in Q2 2026, $47.2M in Q1 2026, $175.0M in Q4 2025) due to heavy capex ($43.2M in Q2 2026 alone) funding capacity expansion. ROE of 15.54% and ROA of 11.38% are solid, and with minimal leverage and strong liquidity, West can self-fund growth and buybacks without external financing, a key differentiator versus more levered med-tech peers.